IgE Inhibitors
2 drugsAbout IgE
Immunoglobulin E (IgE) is an antibody that plays a central role in allergic reactions and parasitic infections. It triggers the release of inflammatory mediators upon binding to allergens, leading to hypersensitivity responses.
IgE is a well-validated drug target for respiratory diseases due to its role in allergic asthma. Currently, there is no genetic evidence directly linking IgE to specific diseases, but its function in allergy is well-established.
Two FDA-approved drugs, XOLAIR (omalizumab) and OMLYCLO, target IgE to alleviate allergy symptoms. These drugs are biologics, including one antibody, developed by Roche and CELLTRION INC.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Chronic Obstructive Pulmonary Disease (COPD) with only 1 trials.
Top Drugs
The IgE drug market is concentrated with only two companies having approved drugs.
The limited number of players suggests high barriers to entry or an underserved market.
Drug Modality Landscape
Modalities
Routes of Administration
IgE is exclusively targeted by antibodies, suggesting it may be a cell-surface or secreted protein.
Exploring alternative modalities like small molecules could provide a competitive advantage.
📈 Modality Evolution
Antibodies pioneered IgE targeting (2003), with other biologics entering more recently (2025).
Clinical Trials 133 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 36 | 32 | 2 | 2 | 94% |
| Phase 2 | 36 | 24 | 2 | 10 | 92% |
| Phase 3 | 29 | 26 | 1 | 2 | 96% |
| Phase 4 | 32 | 18 | 9 | 5 | 67% |
Top Sponsors
By Modality
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved IgE drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting IgE. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2003 - 2025)
The first IgE-targeting drug was approved in 2003, with the most recent approval in 2025.
The 23-year span between approvals indicates a potentially slow-growing but persistent market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 76 clinical trials targeting IgE.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities